2/4
08:29 am
opk
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism [Yahoo! Finance]
Low
Report
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism [Yahoo! Finance]
2/4
08:00 am
opk
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Low
Report
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
2/2
06:50 pm
opk
GeneDx CEO Katherine Stueland talks shaking up rare disease diagnosis [Yahoo! Finance]
Neutral
Report
GeneDx CEO Katherine Stueland talks shaking up rare disease diagnosis [Yahoo! Finance]
1/27
04:12 am
opk
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts [Seeking Alpha]
Low
Report
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts [Seeking Alpha]
1/26
01:31 pm
opk
Miami as a gateway: Taiwan's quiet economic strategy in the Americas [Yahoo! Finance]
Low
Report
Miami as a gateway: Taiwan's quiet economic strategy in the Americas [Yahoo! Finance]
1/14
05:26 pm
opk
Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns [Yahoo! Finance]
Low
Report
Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns [Yahoo! Finance]
1/13
11:21 am
opk
7MM Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease Market Opportunity Assessment and Forecasts 2024-2034 [Yahoo! Finance]
Low
Report
7MM Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease Market Opportunity Assessment and Forecasts 2024-2034 [Yahoo! Finance]
1/12
11:08 am
opk
AI genome sequencing could transform rare disease diagnosis: GeneDx CEO [FOX Business Network]
Low
Report
AI genome sequencing could transform rare disease diagnosis: GeneDx CEO [FOX Business Network]
1/7
03:36 pm
opk
Is GeneDx Holdings (WGS) Pricing Look Attractive After Mixed Long Term Share Performance [Yahoo! Finance]
Low
Report
Is GeneDx Holdings (WGS) Pricing Look Attractive After Mixed Long Term Share Performance [Yahoo! Finance]
1/7
09:17 am
opk
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care [Yahoo! Finance]
Medium
Report
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care [Yahoo! Finance]
1/6
04:11 pm
opk
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
1/6
08:41 am
opk
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth [Yahoo! Finance]
Medium
Report
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth [Yahoo! Finance]
1/5
09:06 am
opk
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025 [Yahoo! Finance]
Low
Report
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025 [Yahoo! Finance]
12/30
09:37 am
opk
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference [Yahoo! Finance]
Low
Report
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference [Yahoo! Finance]
12/21
01:08 am
opk
Low
Report
12/15
08:57 am
opk
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year [Yahoo! Finance]
Low
Report
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year [Yahoo! Finance]
11/21
02:33 am
opk
The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade [Yahoo! Finance]
Low
Report
The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade [Yahoo! Finance]
11/20
08:07 am
opk
OPKO Health (NASDAQ:OPK) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock.
Medium
Report
OPKO Health (NASDAQ:OPK) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock.
11/19
04:05 pm
opk
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/15
11:51 pm
opk
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat [Yahoo! Finance]
Low
Report
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat [Yahoo! Finance]